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Humangrowthhormone(hGH)signaltransductioninitiateswithareceptordimerizationinwhichonemoleculebindstothereceptor
through sites 1 and 2. A sandwich enzyme-linked immunosorbent assay was developed for quantifying hGH molecules that present
helix 4 from binding site 1. For this, horse anti-rhGH antibodies were eluted by an immunoaﬃnity column constituted by sepharose-
rhGH. These antibodies were puriﬁed through a second column with synthetic peptide correspondent to hGH helix 4, immobilized
to sepharose, and used as capture antibodies. Those that did not recognize synthetic peptide were used as a marker antibody. The
working range was of 1.95 to 31.25ng/mL of hGH. The intra-assay coeﬃcient of variation (CV) was between 4.53% and 6.33%, while
the interassay CV was between 6.00% and 8.27%. The recovery range was between 96.0% to 103.8%. There was no cross-reactivity
with human prolactin. These features show that our assay is an eﬃcient method for the determination of hGH.
INTRODUCTION
Diagnosis of growth hormone deﬁciency (GHD) is
usuallybaseduponassessmentofanthropometric param-
etersinpatientswhopresentreducedlevelsofgrowthhor-
mone in response to a pharmacological test [1].
Most of the commercially available immunoassays do
not describe the precise epitope of human growth hor-
mone (hGH) recognized by its primary antibodies, nei-
ther do they take into consideration the possibility of an
assessment of the biological activity of the hGH isoforms.
One single hGH molecule binds to two receptors through
hGH binding sites 1 and 2 [2, 3]. To this date, only a few
immunoassays have employed antibodies that recognize
one of these sites. One of these assays, which has suc-
cessfully employed an antibody that recognizes GH bind-
ing site 2, associated with binding of hGH binding pro-
tein (GHBP) to binding site 1, was estimated to reveal
hGH biological activity, and it was proposed as an im-
munofunctionalassay(IFA)[4].Accordingtotheauthors,
their assay has revealed mutated GH isoforms with im-
paired biological activities, involving either a modiﬁca-
tion in hGH binding site 2 or a mutated hGH binding
site 1 that is unable to bind to GHBP. This IFA and other
bioassays [5, 6, 7, 8] were used to quantify GH bioactive
isoforms that are absent in Kowarski syndrome [9]. The
main features of this syndrome are the high plasma hGH
levels, determined with immunoassays using polyclonal
antibodies, low insulin-like growth factor-I (IGF-I) and
IGF-binding protein-3 (IGFBP-3) concentrations, and a
good response to recombinant human growth hormone
(rhGH) in the ﬁrst months of treatment [10].
An IFA usually presents low immunoreactivity to mu-
tant hGH isoforms, which, by contrast, may be in normal
or high levels revealed by an assay that employs a primary
polyclonal antibody. These assays have employed diﬀer-
entmarkers.Theimmunoradiometricassay(IRMA)[11],
immunoﬂuorometric assay (IFMA) [12], and immuno-
chemiluminometric assay (ICMA) [13] use radioisotope,
ﬂuorescent, or chemiluminescent compounds conjugated
to the marker antibody, respectively. The authors of [11,
12, 13] have reported GH serum levels as low as 0.015,
0.02, and 0.005ng/mL.
This work was designed to develop a sensitive and
speciﬁc horseradish peroxidase (HRPO) enzyme-linked
immunosorbent assay (ELISA) for hGH determination.
Several small sequences of amino acids form the bind-
ing site 1 domain [14]. In the present study, one of the
synthetic peptides with 16 amino acids, which include a
sequence of 6 residues required for hGH binding site 1
[15], was the best peptide to purify a polyclonal antibody
to hGH.144 Juliana F. Moura et al 2004:3 (2004)
MATERIALS AND METHODS
Animalimmunization
One adult female horse was immunized with rhGH
(Genotropin, Pharmacia Diagnostics AB, Upsala, Swe-
den) through subcutaneous applications at 15-day inter-
val. The emulsion for the ﬁrst injection was prepared us-
ing 750µg of rhGH dissolved in 2.5mL of 0.05M phos-
phate buﬀer saline pH 7.4 (PBS) and 2.5mL of Freund’s
complete adjuvant. The remaining 7 applications were
prepared using Freund’s incomplete adjuvant.
Optimal animal immunization was indicated by high
serum concentration of anti-rhGH employing two diﬀer-
ent protocols, immunodiﬀusion test and ELISA. Animal
sera were obtained (1.5L) and immunoglobulins were
precipitated in a saturated ammonium sulfate solution.
Puriﬁcationofanti-rhGHantibodies
Speciﬁc anti-rhGH antibodies were puriﬁed through
immunoaﬃnity columns. One gram of cyanogen
bromide-activated sepharose (CNBr-sepharose) was cou-
pled to 21.5mg of rhGH according to the manufacturer’s
instructions (Pharmacia). Conjugated sepharose-rhGH
was packed into a 6.0mL polystyrene column, washed
and ﬁlled with PBS and 0.05% sodium azide, and
maintained at 4◦C.
Aliquots of horse immunoglobulins dissolved in PBS
circulated through the column at a ﬂow rate of 20mL/h
overnight at 4◦C. Afterwards, the column was washed
with PBS until the absorbance (280nm) of the eluted
solution had returned to baseline. Recovery of the im-
munoglobulins bound to the sepharose-rhGH column
was performed washing the column with 0.1M glycine-
HCl 0.15M NaCl, pH 5.0, until an immunoglobulin peak
had been obtained. Finally, the column was washed with
PBS until the absorbance returned to baseline. Solution
containing anti-rhGH antibodies was dialyzed overnight
at 4◦C in PBS.
Antibodiesanti-helix4ofhGH
A number of peptides were generously provided by
the Peptide Laboratory from UNIFESP (S˜ ao Paulo, SP).
The technique used by this laboratory was reported by
Kates and Albericio [16]. We have prepared several im-
munoaﬃnity columns using several synthetic peptides
designed according to the sequences found in helix 4
and other parts of hGH, but only one was appropriate
for anti-rhGH puriﬁcation. The selected peptide extends
from amino acid residue 166 to 181 and does not include
disulﬁde bridges, but encompasses 6 residues (Asp171,
Lys172, Thr175, Phe176, Arg178, and Ile179) that are im-
portantforthebindingofhGHtothehumanGHreceptor
(hGHR)[15]and12residuesdiﬀerentfromtherespective
portion of human prolactin [17].
Each synthetic peptide (20mg) was immobilized to
1.0g of CNBr-sepharose according to the manufacturer’s
instructions (Pharmacia). Sepharose-helix 4 peptide was
packed into a 6.0mL polystyrene column, washed and
ﬁlledwithPBSand 0.05% sodium azide. This columnwas
maintained at 4◦C.
Aliquots with puriﬁed anti-rhGH antibodies circu-
lated through the sepharose-helix 4 peptide column (or
through other columns prepared with other peptides) at
a ﬂow rate of 20mL/h. Unbound anti-rhGH antibodies
that did not recognize the helix 4 peptide were eluted and
separated to be conjugated with HRPO (later used as sec-
ond anti-hGH antibody). The column was washed with
PBS until the absorbance (280nm) of the eluate returned
to baseline. Samples of eluted anti-rhGH were dialysed
overnightat4◦CinPBS.Tocollectanti-helix4peptidean-
tibodies, the column pH was reduced with 0.1M glycine-
HCl 0.15M NaCl, pH 5.0, and the eluted solution was af-
ter a while dialysed at 4◦C in PBS, overnight. Finally, the
immunoaﬃnity column was washed with PBS until the
absorbance of the eluted solution returned to baseline.
Preparationofanti-rhGHantibodiesforELISA
Anti-rhGH antibodies that did not recognize the helix
4 peptide, eluted from the aﬃnity column, were conju-
gated to HRPO according to the procedure reported by
Nakane and Kawaoi [18].
A 96-well Nunc MaxiSorp plate (Nalge Nunc Interna-
tional, Roskilde, Denmark) was coated overnight at 4◦C
with 100µLo fa1 0 µg/mL solution of anti-helix 4 an-
tibodies in 0.05M carbonate buﬀer, pH 9.6. Afterwards,
the wells were washed with wash buﬀer (0.05% Tween
20 in saline). Each well was ﬁlled with 120µL of block-
ing buﬀer (2% casein in PBS) and the plate was incubated
for 1 hour at 37◦C. After washing, serial dilution of rhGH
(125ng/mL to 0.98ng/mL) in dilution buﬀer (0.25% ca-
sein,0.05%Tween20,PBS)wasaddedtothewellsstarting
from the ﬁrst row. After incubating the plate for 1 hour at
37◦C, it was washed and anti-rhGH HRPO conjugated in
dilution buﬀer was added to the wells with ﬁnal dilutions
of1 : 250,1 : 500,1 : 1000,1 : 2000,1 : 4000,and1 : 8000,
starting from the ﬁrst column (leftto right). After incuba-
tion for 1 hour at 37◦C, the solution was removed and the
wells were washed at least six times and 100µLo fa no r -
thophenilenediamine solution (0.33mg/mL in 0.5M cit-
rate buﬀer, pH 5.2, and 0.4% hydrogen peroxide) were
addedtoeachwell.After15minutesatroomtemperature,
protected from light, the enzymatic reaction was stopped
through the addition of 20µL of 2M sulfuric acid. The
absorbance (492nm) was measured using a Bio-Tek ELX
800 reader.
Samples
This study was approved by the Ethics Committee
from the Hospital of Clinics from the Federal University
of Parana, and serum samples from 73 boys (10.9 ± 3.0
years) and 36 girls (10.1 ± 3.2 years) were collected af-
ter obtaining written consent from their parents. The
patients were submitted to the GH test (GH released2004:3 (2004) ELISA for hGH 145
after clonidine application) according to the established
protocol for growth retardation at the Division of Pedi-
atric Endocrinology ofHospital ofClinics. Time courseof
sample collection for each patient: baseline (before cloni-
dine), 60, 90, and 120 minutes after clonidine administra-
tion.
SandwichELISAwasusedtoquantifyhGHfromthese
patients. The absorbance values from each serum were
plotted against the standard curve obtained with rhGH
and the results were compared with the previously known
hGH measurements from IRMA (MaiaClone, Biodata
Diagnostics, Rome, Italy).
RESULTS
Production,puriﬁcation,andtitrationofantibodies
Serum from rhGH-immunized horse was tested by
immunodiﬀusion in the presence of rhGH 1mg/mL and
the results were positive up to 1 : 4 dilutions. After treat-
ing the animal with one extra injection of rhGH, serum
titres were reanalyzed by ELISA two weeks later, when ad-
equate immunization was revealed by titres of 1 : 256000.
After ammonium sulfate precipitation and dialysis
of whole immunoglobulins, these polyclonal antibodies
were puriﬁed by sepharose-rhGH column and the ﬁ-
nal concentration was 1.6mg/mL. Anti-rhGH antibodies
were eluted through a second column with helix 4 pep-
tide immobilized to sepharose. After dehydration the an-
tibodies ﬁnal concentration was 0.948mg/mL. This anti-
body was used to capture hGH and rhGH. The antibod-
ies that did not recognize helix 4 peptide were conjugated
to HRPO and the best dilution used in all ELISAs was
1 : 1000.
SandwichELISA
The rhGH saturation curve was constructed with the
absorbance data obtained using fresh dilutions of rhGH
(Genotropin, Pharmacia) preparations (Figure 1). The
results were obtained through absorbance plot against
rhGH concentration. There were no diﬀerences between
plates that were coated just before use and those that were
frozen until up to six weeks before the assay. The work-
ing range was at 1.95ng/mL to 31.5ng/mL and the limit
of detection tested (0.12ng/mL) was statistically diﬀerent
from the blank (P = .024).
Intra-assay precision control was assessed by measur-
ing 4 groups of sera pools corresponding to time points
basal (B), 60, 90, and 120 minutes. Each pool was mea-
sured 16 times in the same plate. The interassay coeﬃcient
was obtained by analyzing each of the 4 time points in the
17 diﬀerent assays (Table 1).
The accuracy was evaluated by analytical recovery
in which a known rhGH concentration (6.54ng/mL)
was added to 4 patient samples ranging from 2.76 to
14.08ng/mL. The measured values were within 96.02%
and 103.82% (Table 2).
The linearity of this sandwich ELISA was estimated
through the quantiﬁcation of 4 serum samples (B, 60, 90,
Table 1. Precision of hGH levels measured by anti-helix 4 sand-
wich ELISA.
Assay Time points Mean SD CV
(min) (ng/mL) (ng/mL) (%)
Intra-assay Baseline 2.37 0.15 6.33
60 8.16 0.37 4.53
90 14.62 0.81 5.54
120 7.54 0.47 6.23
Interassay Baseline 2.55 0.18 7.06
60 8.67 0.52 6.00
90 14.87 1.23 8.27
120 7.79 0.52 6.67
Table 2. Analytical recovery of rhGH.
Sample Baseline 60 90 120
hGH (ng/mL) 2.76 8.94 14.08 7.52
rhGH added (ng/mL) 6.54 6.54 6.54 6.54
Measured hGH level (ng/mL) 6.28 6.62 6.79 6.45
Recovery (%) 96.02 101.22 103.82 98.62
and 120 minutes) from a single patient with known hGH
concentrationsthatweredilutedwitheweserum(eweGH
isnotrecognizedbyanti-rhGHantibody).Serumconcen-
tration with less than 3ng/mL lost linearity.
Human prolactin (hPRL) has several similarities with
hGH such as structure and function [19], however, helix
4 peptide has only 4 amino acids in common with hPRL.
There was no cross-reactivity between hPRL from Sigma-
Aldrich, (St Louis, Mo) (3.9 to 500ng/mL) or hPRL from
Abbott calibrator, (Abbott Park, Ill) (1.56 to 200ng/mL)
(Figure 2).
ComparisonwithIRMAandICMA
The measured sera hGH from 109 patients were ob-
tained using the present assay and then compared with
the results from an IRMA (MaiaClone, Biodata Diag-
nostics). Although the hGH concentrations obtained for
both types of assays, for each of the 4 time points of
the clonidine test, were highly correlated (r-values rang-
ing from 0.92 to 0.98), samples from 24 patients were
signiﬁcantly diﬀerent between these 2 assays. In order
to clarify the diﬀerences between IRMA and our sand-
wich ELISA for these 24 patients, their sera were quan-
tiﬁed by a commercial ICMA (Immulite 2000, Diagnostic
Products Corporation, Los Angeles, Calif). The results re-
vealed by ICMA did not clarify the discrepancies found
between sandwich ELISA and IRMA (Table 3).
Despite the diﬀerences among these 3 assays, the cor-
relation(r)rangedfrom0.93(betweenELISAandICMA)
to 0.89 (between ICMA and IRMA). Those patients
(3/109, 2.7%, 2 boys and 1 girl) with growth retardation,
who had normal or high hGH levels revealed by IRMA
and low levels with ELISA, are being further investigated
for possible hGH gene mutations. Patients 4, 13, and 15146 Juliana F. Moura et al 2004:3 (2004)
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Figure 1. Saturation curve for rhGH. The working range was ( ) from 1.95 to 31.25ng/mL. A trend to linearity can be observed at
the interval between 0.24 to 1.95ng/mL (). A trend to a plateau () can be found at high rhGH concentration.
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Figure 2. Estimation of cross-reactivity between both human prolactin, hPRL Sigma () and hPRL Abbott (), and the rhGH
Genotropin, Pharmacia (•).
(Table 3),whohavepresentedgrowthretardationandlow
levels of hGH measured by ELISA, are presently being in-
vestigated for possible mutation in the hGH gene. One of
thesepatientspresentedlowlevelsofinsulingrowthfactor
1, which were normalized after an rhGH test.
DISCUSSION
Ourstudyproposes aprotocolforproductionofpoly-
clonal antibodies with monoclonal antibodies charac-
teristics, in which small synthetic peptides are selected
for puriﬁcation without participating in the animal im-
munization process. In addition, this approach provides
much higher amounts of animal immunoglobulins than
that obtained through the use of hybridoma.
One of the landmarks in the design of hormone im-
munoassays is the speciﬁcity of the antibody for the se-
lected epitope. When such an epitope plays an important
role in binding to the hormone receptor, the assay may be
used to estimate immunoreactivity and bioactivity. Sub-
tle changes in a small epitope caused by point mutations
should be able to prevent its recognition by this antibody.
Usually, the immunoreactivity is measured without pre-
senting any evidence whether the peptide is biologically
active or not [20].
The need for a bioactive assay has been proposed by
Strasburger [21]. de Vos et al [3]h a v er e p o r t e do nt h e
importance of binding sites 1 and 2 of hGH molecule to
dimerization of hGHR; other studies have shown conse-
quences of mutations in these sites [10]c h a r a c t e r i z e db y
Kowarski’s syndrome [9]. Rowlinson et al [22]h a v er e -
ported three site 1 mutants, which had decreased bioac-
tivity mainly when the center of helix 4 was involved.
I nt h ep r e s e n ts t u d y ,w eh a v ed e s c r i b e das a n d w i c h
ELISAforthedetermination ofhGHlevelsinwhichhorse
polyclonal antibodies anti-rhGH was produced, conju-
gated to HRPO or further puriﬁed using immunoaﬃnity
chromatography.ThemainfeatureofthisELISAistheuse2004:3 (2004) ELISA for hGH 147
Table 3. Diﬀerences found among ELISA, ICMA, and IRMA.
Patient ELISA (ng/mL) ICMA (ng/mL) IRMA (ng/mL)
1 19.6 22.2 31.6
2 4.0 3.2 1.9
3 12.0 13.2 15.5
4 4.1 12.4 12.0
5 19.1 23.0 10.7
6 24.5 31.2 35.5
7 11.0 12.2 7.0
8 1.6 1.9 0.45
9 9.1 8.8 5.0
10 9.8 8.2 6.6
11 10.5 10.3 15.5
12 0.3 1.8 1.6
13 6.0 17.5 21.9
14 6.7 9.2 10.0
15 4.9 15.2 11.6
16 11.1 19.7 14.2
17 10.2 9.9 19.7
18 3.5 2.8 5.0
19 19.3 20.2 26.5
20 1.3 1.8 0.9
21 13.9 19.0 10.8
22 2.0 4.9 4.5
23 34.0 36.0 42.9
24 35.2 34.0 40.0
of an antibody against helix 4, a region that contributes to
binding site 1 of hGH. From horse serum with high anti-
bodies titres (1 : 256000) we isolated antibodies that rec-
ognize this portion of binding site 1. For this purpose, a
synthetic peptide (AA 166–181), corresponding to a por-
tion of helix 4, was immobilized to the aﬃnity column.
The horse antibodies fraction that recognizes helix 4
w a sp u r i ﬁ e da n du s e da sac a p t u r ea n t i b o d y .T h es e c o n d
antibody does not bind to the helix 4 epitope, which is a
desirable feature to prevent competition for the same epi-
tope of the capture antibody. This marker antibody, con-
jugated to HRPO according to Nakane and Kawaoi [18],
was used at a 1 : 1000 dilution following assay standard-
ization.
We noticed that with hGH concentration between 3.3
and 11ng/mL there was a linearity close to 100% and the
accuracy had values above 0.98ng/mL. The reproducibil-
ity was assessed through intra- and interassay variation
coeﬃcients ranging from 4.53% to 6.33% and from 6.0%
to 8.27%, respectively. The analytical recovery ranging
from 96.02% to 103.82% demonstrated acceptable values
to conventional assays.
Site 1 of hGH and hPRL presents 12 diﬀerent residues
[17], which may be the reason why our assay did not
cross-react with hPRL. We used concentrations of hPRL
up to 500ng/mL and no cross-reactivity was observed.
This had to be documented because some children or
adult patients under stress conditions have high levels of
serum hPRL. In addition, some pituitary adenomas may
produce both hormones, and a distinction between hGH
and hPRL levels is then necessary.
After standardization of sandwich ELISA, we quanti-
ﬁed 436 samples from 109 children (4 samples/child) who
were submitted to a pharmacological test of clonidine and
had hGH levels determined by IRMA. The obtained re-
sults were compared to those obtained with our sand-
wich ELISA. Despite the high correlation (r-values rang-
ing from 0.92 to 0.98), 24 patients had, between these two
assays, diﬀerent hGH concentrations. These divergences
requiredfurthertestsinacommerciallaboratorythatem-
ploys automated ICMA. The correlation coeﬃcients were
positive, with r ranging from 0.93 (between ELISA and
ICMA) to 0.89 (between ICMA and IRMA), but this anal-
ysis did not clarify the discrepancies found among these
assays (Table 3). Diﬀerences in the methodology and/or
samples conditions may justify such diﬀerences. It is not
surprising that assays with diﬀerent protocols produce
unequal results. These discrepancies are attributed to the
calibrator [23], to GHBP presence [24, 25], and, mainly,
to multiple isoforms of hGH and to the speciﬁcity of
antibodies to several epitopes [21, 23, 25, 26]. Further-
more, in the circulation there are some disulﬁde dimers
of hGH that are less bioactive [27] and several proteolyti-
cally degraded fragments without biological activity [28],
but they could exhibit immunoreactivity depending on
theantibody[27].Agroupof3patients(2.7%,2boysand
1girl),bothgrowingunderthethirdpercentilecurve,had
normal or high hGH levels based on IRMA and low lev-
els using ELISA, which may suggest that these hGH iso-
forms could be mutant ones. Further studies using DNA
sequencinganalysisofthehGH genearenecessaryto con-
ﬁrm this hypothesis.
While most assays were not designed to draw any con-
clusion about hGH bioactivity [5, 6, 7, 8], one study was
able to present a sophisticated immunofunctional assay
[4], but it is many times more expensive than the ELISA
proposed in this study. This IFA uses a monoclonal an-
tibody for receptor binding site 2 and biotin-labeled hu-
man recombinant GH-binding protein (GHBP). The rea-
son for raising antibodies to sites 1 or 2 seems to be much
more of a limitation in the methodology, for its sheer dif-
ﬁculty in their obtaining. In our approach only one of the
antibodies tested anti-helix 4 was considered appropriate
tobeusedasacaptureantibody.Wemaypredict,basedon
theobservedsimilarityoftheresultsobtainedin3samples
from 82 patients, and similar diﬀerences observed among
ELISA, ICMA, and IRMA in 24 patients (Table 3), that
there must be more than one epitope in helix 4, probably
also not involved in GHBP binding site. Site 2 is consti-
tuted by a small number of amino acids while the inter-
face between hGH binding site 1 and the hGHR involves
31aminoacids[14]distributedamonghelices1and4and
loop 1 [3]. A simple approach used to select the capture
polyclonal antibodies was the most important feature in148 Juliana F. Moura et al 2004:3 (2004)
the technique used to develop this ELISA. To some ex-
tent, the smaller the size of the peptide used, the closer
the puriﬁed antibodies from a monoclonal antibody will
be. Obviously, this seems not to be the case in our present
study because the 16-residue peptide is large enough to
present a number of possible epitopes. Six amino acids in
thisregion(Asp171,Lys172,Thr175,Phe176,Arg178,and
Ile179) contribute to binding of hGH to the hGHR [15].
The other important residues involved in binding site 1
were not included, as intended, because the other aﬃn-
ity columns prepared with the peptides containing these
residues were not able to recognize anti-rhGH polyclonal
antibodies.
The immunoaﬃnity chromatography has become a
standard technique in which primary amino groups from
proteins are bound to gel matrices from agarose [29]. The
puriﬁcation method using a synthetic peptide is eﬃcient
for selection of a certain population of antibodies that
are necessary for quantifying any protein whose epitope
plays an important role in the protein function. We can
conclude that this sandwich ELISA is an inexpensive and
eﬃcient method that can be easily adapted to the auto-
mated devices for conﬁrmation of hGH deﬁciency.
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